Black Friday Prize Draw
- 00Days
- 00Hrs
- 00Mins
- 00Secs
Day 1 - ET (Eastern Time, GMT-05:00)
As Q1 of 2025 begins to draw to a close, the healthcare sector is experiencing rapid innovation with the investment landscape evolves in response to new technologies and market demands. Biotechs, healthtechs, and medtechs are at the forefront of this transformation, but face a complex environment of shifting investor priorities and emerging competition. This panel will explore the current state of healthcare investments and deal-making in 2025, expectations for the rest of the year, and insights into how companies can successfully navigate these dynamic waters.
- Analyzing the key factors driving investment in healthcare today and identifying emerging opportunities for growth
- Exploring the role of collaborations, M&A in scaling innovation and securing long-term success
- Comparing the U.S. healthcare investment landscape to global trends and discussing strategies for thriving in a competitive environment
- Christian Schubert - VP & Head, AbbVie Ventures, AbbVie
- Maha Radhakrishnan - Executive Partner, Sofinnova Investments
- Andrew Lam - Managing Director, Head of Biotech Private Equity, Ally Bridge Group
- Evan Rachlin - Co-Founder & Managing Partner, Ascenta Capital
- Emily Park - Principal, DCVC Bio
- Reetika Bhardwaj - Senior Associate, ARCH Venture Partners
- Fabio Pucci - Senior Director, Venture Investments, Leaps by Bayer
- J.C. Lopez - Principal, NEA
- Maite Malet - Investment & Corporate Development, Asabys Partners
- Sourav Sinha - Partner, Bedford Bridge
- Katerina Fialkovskaya - Investment Director, Philips Ventures
- Murielle Thinard McLane - President & Managing Partner, Intuitive Ventures
- Jonathan Machado - Managing Director, Samsung NEXT
- Jeffrey Weness - Head of Digital Investments, Otsuka Precision Health
The Licensing Masterclass is a targeted session designed for biotech companies seeking to forge licensing deals with pharma partners. This masterclass will provide expert guidance on the strategic, financial, and legal aspects of licensing agreements, helping biotech innovators maximize the value of their assets.
Industry veterans will share best practices for identifying and negotiating with potential pharma partners, structuring deals, protecting intellectual property, and navigating the complexities of licensing contracts. Attendees will leave with a clear understanding of how to secure partnerships that drive growth and commercialization of their biotech innovations.
The IPO Masterclass is designed specifically for biotech companies preparing to go public. This session will offer in-depth insights into the IPO process, tailored to the unique needs and challenges of life science innovators.
Led by seasoned industry experts, the masterclass will cover critical aspects of IPO preparation, including regulatory requirements, market timing, investor relations, and post-IPO strategies. Attendees will gain valuable knowledge on how to optimize their public offering, attract the right investors, and ensure long-term success in the public markets.
The M&A Masterclass is tailored for life sciences start-ups aiming to explore M&A opportunities and best practices with larger strategic companies. This session offers strategic insights into the M&A process, equipping emerging biotech and medtech companies with the knowledge to successfully navigate these transformative deals.
Led by experienced M&A professionals, the masterclass will cover key topics such as valuation, deal structuring, due diligence, and post-merger integration. Attendees will learn how to position their companies as attractive acquisition targets, negotiate favorable terms, and align with the strategic goals of large pharma partners.
As the life sciences sector continues to evolve, so too do the funding models and investment strategies that support it. This panel convenes leading venture capitalists to analyze the emerging trends that are redefining how biotech companies secure funding. Attendees will gain insights into innovative financing approaches and the investment opportunities that are shaping the future of life sciences, enabling them to align their strategies with the shifting landscape.
- Analyzing how advancements in digital health technologies and AI are influencing investment decisions and creating new opportunities for funding
- Understanding how venture capitalists are changing their evaluation criteria for biotech investments, including a focus on sustainability, impact, and long-term viability
- Discussing effective strategies for biotech companies to engage with investors, communicate their value propositions, and foster long-term partnerships
- Jim MacKrell - VP Lilly Venture Science, Eli Lilly
- James Buxton - Principal, NEA
- John Boyce - Managing Director & Co-Founder, TigerGene
- Mahesh Narayanan - Managing Partner, Neuvation Ventures
- Eric Snyder - Partner, Venture Investments, Novo Holdings